The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern

Carl Graham, Thomas Lechmere, Aisha Rehman, Jeffrey Seow, Ashwini Kurshan, Isabella Huettnner, Thomas J. A. Maguire, Jerry C. H. Tam, Daniel Cox, Christopher Ward, Mariusz Rac, Anele Waters, Christine Mant, Michael H. Malim, Julie Fox, Katie J. Doores

1 Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, 2 Harrison Wing, Guys and St Thomas’ NHS Trust, London, United Kingdom, 3 Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom

☯ These authors contributed equally to this work.

* katie.door es@kcl.ac.uk

Abstract

COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune responses. We compared the magnitude and breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B cells, in individuals receiving a second dose of BNT162b2 at a short (3–4 week) or extended interval (8–12 weeks) and following a third vaccination approximately 6–8 months later. We show that whilst an extended interval between the first two vaccinations can greatly increase the breadth of the immune response and generate a higher proportion of Spike reactive memory B cells, a third vaccination leads to similar levels between the two groups. Furthermore, we show that the third vaccine dose enhances neutralization activity against omicron lineage members BA.1, BA.2 and BA.4/BA.5 and this is further increased following breakthrough infection during the UK omicron wave. These findings are relevant for vaccination strategies in populations where COVID-19 vaccine coverage remains low.

Author summary

COVID-19 vaccines have been vital in controlling the current pandemic. With the emergence of SARS-CoV-2 viral variants, it is important to understand factors that influence the neutralization breadth of vaccine responses. Here we study the impact of the interval between the 1st and 2nd BNT162b2 vaccine dose on neutralization breadth and how this is further affected by vaccine boosters and breakthrough infections.
Introduction

Development of vaccines against SARS-CoV-2 has been a vital step in controlling the global COVID-19 pandemic. Most approved vaccines use the SARS-CoV-2 Spike antigen to elicit a neutralizing antibody response as well as generating cell-mediated immunity. The Spike glycoprotein interacts with the angiotensin-converting enzyme 2 (ACE2) on host cells and facilitates viral entry. One of the greatest challenges faced by current vaccines has been the emergence of SARS-CoV-2 viral variants of concern (VOCs) that encode mutations in the Spike protein, including alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2) and omicron (sub-lineage members BA.1, BA.2, BA.4 and BA.5). Numerous studies have shown that these Spike mutations can lead to partial escape in convalescent and vaccinee sera, with the greatest reduction in neutralization being observed for omicron sub-lineages [1–5]. Therefore, immunogens and immunization regimes that elicit durable neutralizing antibody (nAb) responses with broad activity against both known and newly emerging variants is highly desirable.

In December 2020, the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine was given approval for use in the UK. The approved regimen was two doses administered at a 3–4-week interval, but in January 2021 a change to UK policy meant that the BNT162b2 booster vaccination was administered with an extended interval of 8–12 weeks. The rationale behind this change was to provide as much of the UK population with some level of immunity in the face of a large wave of SARS-CoV-2 alpha variant infections [6]. Initially, most COVID-19 vaccines required two vaccinations to provide efficacy against the Wuhan (wild-type, WT) alpha and delta VOCs. However, due to waning of vaccine-elicited nAb levels [7] and with the emergence of omicron/BA.1, which encodes >30 mutations in Spike, a third vaccination (either BNT162b2 or mRNA-1273) became recommended. A third vaccine has been shown to increase neutralization titres against omicron/BA.1 [3–5,8] and to restore vaccine efficacy against omicron/BA.1 [9–11]. However, breakthrough infections (BTI) in vaccinated individuals have been observed at increased frequencies compared to previous dominant variants [9–11].

We sought to determine how the interval between the 1st and 2nd BNT162b2 vaccinations impacted on neutralization breadth and potency against current and newly emerging VOCs in the short-term (post 2-doses) and in the long-term (post 3-doses), and how subsequent BTI during the UK omicron wave (January to February 2022) affected neutralization of newer omicron sub-lineage members. We show that broader plasma neutralizing activity is observed when the 2nd dose is given with extended 8–12 week interval (extended group) compared to those receiving the 2nd dose with a 3–4 week interval (short group). However, the advantage of the extended booster to neutralization is not displayed following a 3rd vaccination where robust neutralization of omicron lineages members (BA.1, BA.2, BA.4 and BA.5) is observed in both groups. Finally, we show that omicron BTI further boosts the neutralization activity against omicron sub-lineages. Overall, this research provides insights into optimizing vaccine regimens to provide the greatest neutralization breadth.

Results

Vaccine cohort description

Plasma and PBMCs were collected from individuals receiving the BNT162b2 vaccine either with a short booster interval (3–4 weeks, n = 19, short-group) or an extended booster interval (8–12 weeks, n = 28, extended-group) (Fig 1A). For the extended-group blood was collected prior to vaccination (baseline), 3 weeks post 1st dose (post 1st) and post 2nd dose (post 2nd). For the short-group, blood was only collected post 2nd dose (post 2nd). Blood was also collected
from both groups 6 months post 2nd vaccine dose (6m-post 2nd) and further samples was taken 3–4 weeks and 6-months post 3rd vaccine (post 3rd and 6m-post 3rd, respectively). For individuals experiencing a BTI, blood was also collected post infection (post BTI).

The short-group was 84.2% female, with an average age of 44.1 years (standard deviation, 11.1 years) whereas the extended-group was 53.6% female, with a slightly lower average age of 38.0 years (standard deviation, 11.8 years) (Fig 1B and 1C). Information on previous SARS-CoV-2 infection was recorded at each blood draw. In addition, as utilised previously [12,13], the presence of IgG to nucleoprotein and Spike was utilized to determine previous asymptomatic SARS-CoV-2 infections or infections occurring prior to community PCR testing in those with a baseline sample (extended-group). For those without a baseline sample, the presence of IgG to nucleoprotein post 2nd dose was used. Previous infection was reported and/or detected in 3/19 from the short-group and in 10/28 from the extended-group (Fig 1D), and

https://doi.org/10.1371/journal.ppat.1010882.g001
SARS-CoV-2 naïve individuals were grouped separately for analysis. All participants reporting infection experienced mild symptoms that did not require hospitalization. Based on the reported timing of infection (February to October 2020), the majority of the infections were presumed to be with the ancestral strain. However, two participants in the extended-group reported infections in December 2020 when alpha was becoming dominant in the UK.

The median interval between vaccine doses was 26 days (interquartile range, 3.5 days) for the short group and 77.0 days (interquartile range, 11.3 days) in the extended group (Fig 1E). Participants in the short-group received their COVID-19 vaccine earlier due to their roles as front-line healthcare workers rather than being deemed at higher risk due to co-morbidities. One participant in the short-group was Type-2 diabetic and one participant in the extended-group was receiving treatment for rheumatoid arthritis and the remaining donors were otherwise considered healthy.

**Anti-Spike IgG levels are similar in short and extended booster groups**

IgG binding to recombinant Wuhan-1 Spike was measured by ELISA and the half-maximal binding (ED$_{50}$) calculated (Fig 2). As reported previously [14–18], individuals who had experienced a SARS-CoV-2 infection prior to vaccination had higher Spike IgG levels compared to naïve individuals after the 1st vaccine dose (post 1st) (Fig 2B). However, similar levels of anti-Spike IgG were observed in the SARS-CoV-2 naïve and convalescent donors following the 2nd vaccination (post 2nd) (Fig 2A and 2B).

For SARS-CoV-2 naïve individuals, comparison of ED$_{50}$ between the short and extended groups showed no statistical differences post 2nd, although there was a trend towards higher levels in the extended group (Fig 2C). Both groups showed waning of the anti-Spike IgG levels 6 months post 2nd vaccine (6m-post 2nd) which were subsequently boosted after participants received a 3rd vaccine dose (post 3rd) (Fig 2A and 2B).

**Previous SARS-CoV-2 infection leads to higher nAb titres following the first vaccine dose**

Next, plasma neutralization breadth and potency were determined using HIV-1 lentiviral particles pseudotyped with either the SARS-CoV-2 Spike of Wuhan-1 (vaccine strain), alpha, delta, beta or omicron/BA.1 VOCs and a HeLa cell line stably expressing ACE2 as the target cell [13]. We have previously shown that the ID$_{50}$ values generated using the pseudotype assay correlate well with ID$_{50}$ values obtained using a live virus neutralization assay [13,19]. Analysis of neutralizing responses after a single vaccine dose (post 1st) was only conducted on the extended-group due to sample availability (Fig 1A). Consistent with previous studies [14–18], following 1-dose of BNT162b2, geometric mean titres (GMTs) against the matched vaccine strain (Wuhan-1, wildtype, WT) were higher in those who had a SARS-CoV-2 infection prior to vaccination (Fig 3A–3C). Furthermore, previously infected individuals showed greater neutralization breadth against VOCs (Fig 3A–3C).

**An extended interval between the 2nd vaccine dose enhances the breadth of the neutralizing antibody response**

Following two doses of BNT162b2 in SARS-CoV-2 naïve individuals, GMTs against the matched vaccine strain (Wuhan-1, WT) were similar between the short and extended booster groups (Fig 3D–3F). In both the short and extended-groups, higher GMTs were observed for individuals that had a SARS-CoV-2 infection prior to vaccination (Fig 3G–3I) [14–18]. In SARS-CoV-2 naïve individuals (Fig 3D and 3E), the broadest neutralization activity against
VOCs was observed in the extended booster group where a modest 1.1–1.4-fold reduction in neutralization was observed against alpha, delta, mu and beta and a 4.8-fold reduction against omicron/BA.1 (Fig 3E). For those in the short-group, a larger reduction in neutralization potency against VOCs was observed, with greater reductions against beta (6.1-fold) and omicron (14.2-fold) (Fig 3D). Comparison between GMTs of the short and extended booster groups showed a significantly reduced potency against mu, beta and omicron/BA.1 VOCs in the short booster group (Fig 3F). Although overall GMTs against VOCs were higher in previously infected vaccinees (Fig 3G–3I), the extended booster group also showed higher GMTs against beta and omicron/BA.1 than the short booster group. However, this difference did not reach significance due to the small sample size (Fig 3I).

To determine whether the extended booster generated neutralization breadth beyond SARS-CoV-2 VOCs, neutralization was also measured against SARS-CoV-1 which shares 73%
sequence [20] similarity with Spike of SARS-CoV-2. Although neutralization titres were generally low, individuals receiving the extended booster showed low levels of SARS-CoV-1 neutralization (Fig 3J) with a GMT that was higher than in the short-group.

**An extended vaccine interval enhances the magnitude of the memory B cell response**

To further examine how vaccine interval impacts on the B cell response, we next measured the frequencies of Spike-reactive memory B cells in the short and extended booster groups using flow cytometry (Figs 4A, 4B and S1A) [14,21]. The frequency of Wuhan-1 Spike-reactive memory B cells was measured in pre-vaccination samples (baseline) for the extended booster group only (due to sample availability) and in both groups following the 2nd vaccination (post 2nd). Overall, where paired samples were available, the overall frequency of memory B cells did not change over the course of the analysis (S1B Fig). Participants who had a SARS-CoV-2 infection prior to vaccination had a distinct population of Spike reactive memory B cells in the pre-vaccine baseline sample (mean 0.20%, range 0.10–0.34%) compared to naïve individuals (mean 0.02%, range 0.01–0.06%) (Fig 4C). Following two vaccine doses, the percentage of Spike-reactive memory B cells increased independent of prior SARS-CoV-2 exposure (Fig 4C).

In SARS-CoV-2 naïve participants, a higher frequency of Spike reactive memory B cells was observed in the extended booster group (mean 0.52%, range 0.20–2.36%) compared to the short booster group (mean 0.19%, range 0.07–0.38%) after the 2nd vaccine dose (Fig 4C). When considering the frequency of Spike-reactive B cells in previously infected vaccinated donors, the percentage (mean 0.67%, range 0.24–1.71%) was similar to SARS-CoV-2 naïve individuals in the extended group.

The isotype of the Spike-reactive memory B cells was considered further (Fig 4D). In samples collected from previously infected individuals prior to vaccination, an average 64.5% of the Spike-reactive memory B cells were IgG positive (Fig 4D) and the average percentage increased upon vaccination to 81.8% (Fig 4D) suggesting an improvement in the quality of the response. In COVID-19 naïve individuals, a higher percentage of IgG+ Spike-reactive memory B cells was seen in the extended-booster group (86.5%) compared to the short-booster group (74.5%). A positive correlation between the percentage of Spike-reactive memory B cells and the ED50 and ID50 (Fig 4E and 4F) was observed after two vaccine doses independent of booster interval or previous SARS-CoV-2 exposure.
Fig 4. Higher percentage of SARS-CoV-2 Spike-reactive memory B cells are detected in the extended booster group. Percentage of Spike-reactive memory B cells were determined by flow cytometry. A) Example pre-bleed (baseline) PBMC staining for SARS-CoV-2 naïve individual. B) Example post 2nd vaccine PBMC staining for SARS-CoV-2 naïve individual. Example of full flow analysis shown if S1A Fig. C) Percentage Spike-reactive memory B cells at baseline and post 2nd vaccine were determined by flow cytometry. Previously infected individuals shown in red/
Overall, an extended period between the first and second vaccine dose increases the magnitude of the Spike-specific B cell response.

Neutralizing antibody levels decline at 6 months but are boosted and neutralization broadened by a third vaccine dose

To understand the durability of the nAb response following two vaccine doses, neutralization titres were measured 6 months post second vaccine dose (6m-post 2nd). Plasma neutralization activity against all VOCs (WT, alpha, delta, beta and omicron (BA.1)) had declined in both groups (Fig 5A–5D) as reported in other recent studies [4,8,22]. Although the neutralization of the most antigenically distant VOCs (beta and omicron/BA.1) had declined, titres remained higher in the extended booster group compared to the short booster group (Fig 5A and 5B).

In September 2021, a vaccine booster programme was initiated in the UK and blood was collected from individuals 3-weeks after receiving a 3rd vaccine dose (post 3rd). The impact on IgG levels to Spike and neutralization breadth and potency was measured. The third vaccine dose (post 3rd) increased Spike IgG binding (Fig 2) and the plasma neutralizing activity (Fig 5A–5D) compared to 6 months post 2nd vaccine in both groups. Whereas after the 2nd dose there had been a clear distinction in neutralization breadth between the short and extended booster groups, following administration of a third vaccine dose the neutralizing titres against WT, alpha, delta, beta and omicron/BA.1 were very similar (Fig 5A–5D). Importantly, a 3rd vaccination with ancestral SARS-CoV-2 spike increased neutralization breadth against the most highly diverse beta and omicron/BA.1 variants (Fig 5A–5D). Overall, the reduced neutralization breadth observed in the short booster group after two vaccine doses is rescued following a third vaccine dose.

Broader neutralization is associated with have higher avidity against Spike

Antibody binding avidity has been associated with antibody maturation [23–27]. To determine whether enhanced neutralization breadth was related to higher avidity of antibody binding in the extended booster group we next measured an avidity index for samples collected 3-weeks and 6 months after the second vaccine dose (post 2nd and 6m-post 2nd) and 3-weeks after the third vaccine dose (post 3rd). The avidity was measured by comparing the area under the curve in ELISA, with and without an 8M Urea washing step. For SARS-CoV-2 naïve individuals post 2nd dose, the extended booster group had a significantly higher avidity index than the short booster group (Fig 6A). However, this difference was reduced when comparing previously infected individuals. The avidity index 6 months post 2nd vaccine (6m-post 2nd) was largely unchanged (Fig 6B). Following the 3rd vaccination (post-3rd) where neutralization breadth was similar across the two groups, the avidity index increased in both groups and the difference in avidity index between the short and extended groups was no longer significant (Fig 6C). The avidity index 3-weeks after 2nd vaccine dose (post 2nd) was correlated with the ID50 against each VOC (Fig 6E). No significant correlation was observed for WT. However, the correlation coefficient was greatest for beta and omicron/BA.1 which are most antigenically distant to the vaccine strain and suggests that avidity may be a good indicator VOC cross-
reactivity. The avidity index also correlated with the % of Spike-reactive memory B cells (Fig 6D).

**Neutralization of BA.2 and BA.4/5 sub-lineages**

Since omicron/BA.1 became the dominant global variant worldwide, several related SARS-CoV-2 omicron sub-lineages have been reported that encode unique amino acid changes in Spike. BA.2 has driven a recent wave in the UK and encodes 21 identical mutations to BA.1 (including K417N, N440K and E484A) and 8 additional mutations across NTD and RBD. BA.4 and BA.5, which encode identical Spikes proteins, are thought to be driving a 5th wave in South Africa [28]. The BA.4/BA.5 Spike is similar to BA.2 but has additional mutations delta69-70, L452R and F486V and lacks the Q493R mutation. Emergence of these highly
Fig 6. IgG binding avidity increases with vaccine boosting. Avidity index for IgG binding to Spike was measured A) post 2\textsuperscript{nd}, B) 6 months post 2\textsuperscript{nd} and C) post 3\textsuperscript{rd} and compared across groups. Avidity index was calculated by comparing the area under the curve (AUC) with/without an 8M Urea washing step. D’Agostino and Pearson tests were performed to determine normality. Based on this result, differences between groups were assessed using a Kruskal-Wallis test with Dunn’s multiple comparisons post hoc. D) Correlation between avidity index and % Spike-reactive memory B cells. (Spearman’s correlation, r; a linear regression was used to calculate the goodness of fit, $r^2$). E) Correlations between avidity index and ID\textsubscript{50} against VOCs following 2-doses of BNT162b2 vaccine.

https://doi.org/10.1371/journal.ppat.1010882.g006
transmissible sub-lineages has led to an increased rate of BTIs and, within the cohort described here, thirteen participants (6 and 7 in the short- and extended-groups, respectively) experienced BTI between mid-December 2021-March 2022. The average time between 3rd vaccine dose and BTI was 141 days (standard deviation 39 days) and 52 days (standard deviation 24 days) for the short- and extended-groups, respectively. In mid-December BA.1 made up >80% of UK infections and the BA.1 and BA.2 sub-lineages made up 95% of infections from mid-January [29]. Therefore, BTIs in participants were presumed to be caused by BA.1 or BA.2 VOCs (post-BTI). Blood was also collected from six participants 6 months post 3rd dose (6m-post 3rd).

To assess susceptibility to the recently reported BA.4/BA.5 variants and to determine the impact of BA.1/BA.2 BTI on the antibody response, we measured neutralization against D614G, BA.1, BA.2 and BA.4/BA.5 following three BNT162b2 doses (at 3-weeks and 6-months post 2nd dose) and in those who subsequently experienced a BTI (3-weeks post-BTI) (Fig 7). Due to the smaller number of samples available, all plasma were considered together for analysis. For plasma collected 3-weeks post 3rd vaccine dose (post-3rd), good neutralization against BA.1, BA.2 and BA.4/5 was detected but GMTs were slightly decreased compared to D614G, with the greatest reduction being 2.2-fold against BA.4/5 (Fig 7A). Six months post 3rd vaccine dose (6m-post 3rd), neutralization titres had decreased against all variants (Fig 7B and 7D) as seen six months post 2nd vaccine dose (Fig 5). However, in those who experienced a BA.1/BA.2 BTI (post-BTI) neutralization titres increased against all variants compared to post 3rd vaccine and robust cross-neutralization of all omicron sub-lineages was detected (Fig 7C and 7E). The largest fold increase in GMT following BTI was observed against BA.1 and BA.2 (Fig 7E).

Overall, a third vaccine dose generates neutralization against omicron sub-lineages BA.1, BA.2 and BA.4/5 which is further enhanced by BA.1/BA.2 BTI.

**Discussion**

Elicitation of nAbs with broad activity against both known and newly emerging variants is highly desirable and vital in controlling the current COVID-19 pandemic. Here we studied the impact of vaccine interval on the breadth and potency of the SARS-CoV-2 neutralizing antibody response. We showed that an extended interval between the 1st and 2nd dose of the BNT162b2 vaccine enhances neutralization breadth initially. However, a third vaccine dose generated a robust and broad neutralizing response against VOCs independent of the interval between 1st and 2nd vaccine doses. It has been extensively reported that ‘hybrid’ immunity, immunity derived from SARS-CoV-2 infection followed by vaccination, leads to superior neutralization following 1-dose of COVID-19 vaccine [14–18]. Our results showing higher antibody binding and neutralization in previously infected individuals receiving one BNT162b2 dose are consistent with these reports.

Here, we show than an extended interval between the 1st and 2nd vaccine dose enhances the immune response in four ways. Firstly, and similar to previous reports, there is an increase in IgG binding (ED₅₀) to Spike in the extended booster group following the 2nd immunization [25,30,31] and secondly, the Spike-reactive IgG bind with higher avidity [25]. Thirdly, broader neutralizing activity against VOCs (including BA.1) is generated [32,33]. Finally, a higher percentage of Spike-reactive IgG⁺ memory B cells is detected in SARS-CoV-2 naïve individuals receiving an extended booster. Binding avidity correlated most strongly with the ID₅₀ against the most antigenically distinct VOCs. The higher binding avidity in the extended group suggests that antibodies have undergone higher levels of antibody maturation [23–26]. Indeed, wider SARS-CoV-2 neutralization breadth has been associated with increased somatic hypermutation [14,34–36]. We have recently reported that mAbs isolated from an individual
Fig 7. Neutralization against omicron sub-lineages following 3 vaccine doses and/or BA.1/BA.2 breakthrough infection.
Neutralization breadth and potency was measured against D614G, BA.1, BA.2 and BA.4/BA.5. Analysis of sera collected A) 3-weeks post 3rd BNT162b2 vaccine dose (post 3rd), B) 6-months post 3rd vaccine (6m-post 3rd) and C) following breakthrough infection (post-BTI) (presumed to be BA.1 or BA.2). D) Comparison of titres 3-weeks (post 3rd) and 6-months post 3rd boost (6m-post 3rd). E) Comparison of titres 3-weeks post 3rd boost (post 3rd) and following BTI (post-BTI). Samples from a single individual are joined.
receiving 2-doses of the ChadOx1 AZD1222 vaccine at a 12-week interval were more highly mutated than those isolated from SARS-CoV-2 convalescent donors and displayed greater neutralization breadth [34]. Several studies have shown that mRNA vaccination leads to a robust memory B cell response and induces persistent germinal centre reactions that continue for months after primary vaccination [14,21,37,38]. Therefore, a longer interval between the 1st and 2nd vaccine dose would allow extended germinal centre reactions to take place, leading to increased levels of somatic hypermutation and higher affinity to vaccine antigen.

Neutralization titres decreased 6 months post 2nd vaccine dose [22]. However, consistent with previous research, we show that titres are boosted following the 3rd BNT162b2 vaccination. Importantly, neutralization breadth increased against beta and omicron sub-lineages independent of the interval between the 1st and 2nd vaccine doses leading to overall similar levels of cross-neutralizing activity in both the short and extended booster groups. This increase in neutralization breadth was accompanied by an increase in the Spike-reactive IgG binding avidity in the short booster group, indicative of continued affinity maturation. Nussenzweig and co-workers identified antibody lineages that had undergone further somatic hypermutation following a 3rd dose of COVID-19 mRNA vaccine and these mAbs had superior neutralization breadth and potency [39]. Relevant to the COVID-19 pandemic at the time of writing (June 2022), neutralization against the antigenically distant VOCs BA.1 [3–5,8], BA.2 [2,40,41] and BA.4/BA.5 [42–44] also increased following a 3rd vaccine dose in both groups.

Following BTI during the UK BA.1 or BA.2 wave, neutralization titres against D614G, BA.1, BA.2 and BA.4/BA.5 increased in this cohort independent of previous SARS-CoV-2 infection. The fold increases in GMT were larger against Omicron sub-lineages compared to against D614G. Increases in omicron sub-lineage neutralization following omicron BTI has been observed in other cohorts [45–47]. Furthermore, boosting mRNA vaccinated mice with an omicron/BA.1 based mRNA vaccine increased serum neutralization activity and protection against omicron/BA.1 [48]. Recent studies indicate that the increase in cross-neutralizing activity is mostly driven by re-activation of B cell clones initially generated through vaccination with Wuhan-1 Spike that cross-react with the VOC, with little evidence of the generation of a de novo VOC-specific antibody response [46,49,50]. These observations are contradictory to recent reports suggesting that antibody responses to omicron/BA.1 were limited following an omicron BTI in triple vaccinated donors who had been infected prior to vaccination [51].

The findings of this study are applicable in populations where COVID-19 vaccine coverage remains low and where there is limited vaccine supply. In vaccine naïve populations, an extended interval will likely be beneficial through generation of broader antibody-based immunity against VOCs in the first six months following the 2nd vaccine dose. Indeed, vaccine effectiveness was shown to be significantly higher in those receiving a longer interval between mRNA doses [52,53]. However, whilst there is broader activity following the 2nd vaccine dose in the extended group, there would be a longer period following the 1st vaccine in which antibody titres will remain low and narrow which in turn may lead to a higher risk of infection during this period. This is particularly relevant in vulnerable patient populations, e.g. cancer patients [54–57] and those on immunosuppressive treatment [58,59], where many participants failed to seroconvert following a single vaccine dose. Indeed, UK policy was changed to allow these patient groups a 2nd vaccine dose 3–4 weeks later. Importantly, despite the interval

https://doi.org/10.1371/journal.ppat.1010882.g007
between the 1st and 2nd vaccine doses, a third vaccine dose increases neutralization against the current VOCs including omicron sub-lineages BA.1, BA.2, BA.4 and BA.5. This study does not assess whether the broader neutralization response in the extended-group reduced breakthrough infections. The longer interval in the short-group between 3rd vaccine and BTI is likely associated with the timing of 3rd vaccine dose administration and the UK omicron infection wave. The short-group received a 3rd vaccine in early September 2021 whereas the extended-group received the 3rd dose between November-December 2021.

A limitation of this study is the relatively small sample size in each group which limits the power of the statistical analysis, and it does not allow the assessment of how timing of prior SARS-CoV-2 infection influences antibody responses following vaccination. Furthermore, the impact on cell-mediated immune responses has not been investigated. However, Hall et al have previously show that no significant differences in Spike-specific polyfunctional CD4+ T cell responses between the short and extended groups [60] whereas Payne et al reported higher levels of these cells in the extended group [30].

In summary, in a SARS-CoV-2 naïve population, an extended interval between the 1st and 2nd doses of BNT162b2 leads to an increased neutralization breadth, Spike binding avidity and frequency of Spike-reactive memory B cells. However, this advantage is lost when a 3rd vaccine dose is administered 6–8 months later where broad neutralization against current omicron sub-lineages is observed in both groups. These findings provide insights into optimizing vaccine regimens to provide the greatest neutralization breadth.

Materials and methods

Ethics statement

This study used human samples collected with written consent as part of a study entitled “Antibody responses following COVID-19 vaccination”. Ethical approval was obtained from the King’s College London Infectious Diseases Biobank (IBD) (KDJF-110121) under the terms of the IDB’s ethics permission (REC reference: 19/SC/0232) granted by the South Central–Hampshire B Research Ethics Committee in 2019.

Protein expression and purification

Recombinant Spike and nucleoprotein for ELISA were expressed and purified as previously described [12,13].

ELISA (Spike)

96-well plates (Corning, 3690) were coated with antigen at 3 μg/mL overnight at 4˚C. The plates were washed (5 times with PBS/0.05% Tween-20, PBS-T), blocked with blocking buffer (5% skimmed milk in PBS-T) for 1 h at room temperature. Serial dilutions of plasma in blocking buffer were added and incubated for 2 hr at room temperature. Plates were washed (5 times with PBS-T) and secondary antibody was added and incubated for 1 hr at room temperature. IgG was detected using Goat-anti-human-Fc-AP (alkaline phosphatase) (1:1,000) (Jackson: 109-055-098). Plates were washed (5 times with PBS-T) and developed with AP substrate (Sigma) and read at 405 nm.

ELISA to determine previous SARS-CoV-2 infection (Nucleoprotein and Spike)

96-well plates (Corning, 3690) were coated with antigen (Spike or nucleoprotein) at 3 μg/mL overnight at 4˚C. The plates were washed (5 times with PBS/0.05% Tween-20, PBS-T), blocked
with blocking buffer (5% skimmed milk in PBS-T) for 1 h at room temperature. Plasma was
diluted at 1:25 in blocking buffer were added and incubated for 2 hr at room temperature.
Plates were washed (5 times with PBS-T) and secondary antibody was added and incubated
for 1 hr at room temperature. IgG was detected using Goat-anti-human-Fc-AP (alkaline phos-
phatase) (1:1,000) (Jackson: 109-055-098). Plates were washed (5 times with PBS-T) and de-
veloped with AP substrate (Sigma) and read at 405 nm. As reported previously [12], baseline
plasma (extended-group) with OD values 4-fold above background for both IgG to Nucleoprotein
and IgG to Spike were considered previously infected with SARS-CoV-2. Where baseline
samples were not available (short-group) then IgG to N alone was used to determine a previ-
ous SARS-CoV-2 infection.

**Avidity ELISA**
The ELISA was carried out as described above. A 4-point titration (starting at 1:25, 1:4 dilution
series) was used. After incubation of plasma, one half of the plate was incubated with 8M Urea
and the other half incubated with PBS for 10mins before washing 5-time with PBS-T. The area
under the curve was determined in Prism (Log dilution). The avidity index was calculated
using the following formula:

\[
\text{Avidity index} = 100 \times \left( \frac{\text{Area under curve with 8M Urea}}{\text{Area under curve with no Urea}} \right)
\]

**Neutralisation assay with SARS-CoV-2 pseudotyped virus**
Pseudotyped HIV-1 virus incorporating the SARS-CoV-2 Spike protein (either wuhan-1,
D614G, alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.1), mu (B.1.621), omicron (BA.1, BA.2 or
BA.4/5) were prepared as previously described [13,61]. Viral particles were produced in a 10
cm dish seeded the day prior with 5x10^6 HEK293T/17 cells in 10 ml of complete Dulbecco’s
Modified Eagle’s Medium (DMEM-C, 10% FBS and 1% Pen/Strep) containing 10% (vol/vol)
foetal bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were trans-
fected using 90 μg of PEI-Max (1 mg/mL, Polysciences) with: 15μg of HIV-luciferase plasmid,
10 μg of HIV 8.91 gag/pol plasmid and 5 μg of SARS-CoV-2 spike protein plasmid [62,63].
The supernatant was harvested 72 hours post-transfection. Pseudotyped virus particles was fil-
tered through a 0.45μm filter, and stored at -80˚C until required.

Serial dilutions of plasma samples (heat inactivated at 56˚C for 30mins) were prepared with
DMEM media (25μL) (10% FBS and 1% Pen/Strep) and incubated with pseudotyped virus
(25μL) for 1-hour at 37˚C in half-area 96-well plates. Next, Hela cells stably expressing the
ACE2 receptor were added (10,000 cells/25μL per well) and the plates were left for 72 hours.
Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit (Promega), using
a Victor X3 multilabel reader (Perkin Elmer). Each serum sample was run in duplicate and
was measured against the five SARS-CoV-2 variants within the same experiment using the
same dilution series.

**FACS analysis of Spike-specific memory B cells**
Flow cytometry of cryopreserved PBMCs was performed on a BD FACS Melody as previously
described. SARS-CoV-2 Wuhan-1 Spike was pre-complexed with the streptavidin fluorophore
(Alexa-488) at a 4:1 molar ratio prior to addition to cells. PBMCs were incubated with Fc
block for 15 minutes at 4˚C. PBMCs were stained with anti-CD3-BV510 (Biolegend), anti-
CD19-PerCP-Cy5.5 (Biolegend), anti-IgD-Pacific Blue (Biolegend), anti-CD27-BV785 (Biolegend), anti-CD38-APC-Cy7 (Biolegend), anti-IgG-PE-Cy7 (BD Biosciences), anti-IgM-PE (Biolegend) and Spike-Alexa Fluor 488 for 1 hour at 4˚C. PBMCs were washed with PBS and stained with live/dead for 1 hour at 4˚C.

Supporting information

S1 Fig. SARS-CoV-2 Spike-reactive memory B cells measured before and after vaccination.
A) Example FACS gating for pre-vaccination sample (baseline) and from post-vaccination sample (post 2nd) from SARS-CoV-2 naïve individual. B) Frequency of memory B cells in the total B cell population at baseline and post 2nd vaccine for matched donors.

Acknowledgments

We thank Philip Brouwer, Marit van Gils and Rogier Sanders for the Spike protein construct, Leo James and Jakub Luptak for the N protein, Wendy Barclay for providing the B.1.617.2, BA.1, BA.2 and BA.4/BA.5 Spike plasmids and James Voss and Deli Huang for providing the Hela-ACE2 cells. The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP.

Author Contributions

Conceptualization: Carl Graham, Jeffrey Seow, Michael H. Malim, Julie Fox, Katie J. Doores.
Data curation: Carl Graham, Christine Mant, Katie J. Doores.
Formal analysis: Carl Graham, Jeffrey Seow, Katie J. Doores.
Funding acquisition: Michael H. Malim, Julie Fox, Katie J. Doores.
Investigation: Carl Graham, Thomas Lechmere, Aisha Rehman, Jeffrey Seow, Ashwini Kurshan, Isabella Huettner, Thomas J. A. Maguire, Jerry C. H. Tam, Daniel Cox, Christopher Ward, Mariusz Racz, Anele Waters, Katie J. Doores.
Methodology: Carl Graham, Thomas Lechmere, Aisha Rehman, Ashwini Kurshan, Isabella Huettner, Thomas J. A. Maguire, Jerry C. H. Tam, Daniel Cox, Christopher Ward, Mariusz Racz, Anele Waters, Christine Mant, Katie J. Doores.
Project administration: Christopher Ward, Mariusz Racz, Anele Waters, Christine Mant, Katie J. Doores.
Software: Carl Graham.
Supervision: Michael H. Malim, Julie Fox, Katie J. Doores.
Writing – original draft: Carl Graham, Katie J. Doores.
Writing – review & editing: Michael H. Malim, Julie Fox.

References

1. Lechmere T, Snell LB, Graham C, Seow J, Shalim ZA, Charalampous T, et al. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. mBio. 2022:e0379821. Epub 2022/03/18. https://doi.org/10.1128/mbio.03798-21 PMID: 35297676.
2. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect Dis. 2022. Epub 2022/04/16.
3. Doria-Rose NA, Shen X, Schmidt SD, O’Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv:10.1101/2021.12.15.21267805v2. [preprint] 2021. Available from: https://www.medrxiv.org/content/10.1101/2021.12.15.21267805v2 (cited 2022 July 6).

4. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022; 28(3):477–80. Epub 2022/01/21. https://doi.org/10.1038/s41591-021-01676-0 PMID: 35046572; PubMed Central PMCID: PMC8767537.

5. Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, et al. Three-dose vaccine elicits neutralizing antibodies against omicron. Lancet. 2022. Epub 2022/01/23. https://doi.org/10.1016/S0140-6736(22)00092-7 PMID: 35065005; PubMed Central PMCID: PMC8769665.

6. Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination programme for maximum short-term impact. 2021. Available from: https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvii-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact. (cited 2022 July 6)

7. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. Epub 2021/10/28. https://doi.org/10.1056/NEJMoa2114228 PMID: 34706170; PubMed Central PMCID: PMC8609604.

8. Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022. Epub 2022/05/07. https://doi.org/10.1016/j.cell.2022.04.009 PMID: 35523182; PubMed Central PMCID: PMC8989683.

9. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med. 2022; 386(19):1804–16. Epub 2022/03/10. https://doi.org/10.1056/NEJMoa2200797 PMID: 35263534; PubMed Central PMCID: PMC8929389.

10. Andrews N, Stowe J, Kinsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532–46. Epub 2022/03/07. https://doi.org/10.1056/NEJMoa2119451 PMID: 35249272; PubMed Central PMCID: PMC8908811.

11. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639–51. Epub 2022/01/22. https://doi.org/10.1001/jama.2022.0470 PMID: 35060999; PubMed Central PMCID: PMC8848203.

12. Pickering S, Betancor G, Galao RP, Merrick B, Signell AW, Wilson HD, et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 2020; 16(9):e1008817. Epub 2020/09/25. https://doi.org/10.1371/journal.ppat.1008817 PMID: 32970782; PubMed Central PMCID: PMC7514033.

13. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020; 5(12):1598–607. Epub 2020/10/28. https://doi.org/10.1038/s41564-020-00813-8 PMID: 33106674.

14. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci Immunol. 2021; 6(58). Epub 2021/04/17. https://doi.org/10.1126/sciimmunol.abi6950 PMID: 33858945; PubMed Central PMCID: PMC8158969.

15. Manisty C, Otter AD, Treibel TA, McKnight A, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021; 397(10279):1057–8. Epub 2021/03/01. https://doi.org/10.1016/S0140-6736(21)00501-8 PMID: 33640038; PubMed Central PMCID: PMC7972310.

16. Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021. Epub 2021/03/27. https://doi.org/10.1126/science.abg9175 PMID: 3376994; PubMed Central PMCID: PMC8113945.

17. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021. Epub 2021/05/02. https://doi.org/10.1126/science.abg9175 PMID: 33931567; PubMed Central PMCID: PMC8166614.
18. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021; 325(14):1467–9. Epub 2021/03/02. https://doi.org/10.1001/jama.2021.3341 PMID: 33646292; PubMed Central PMCID: PMC7922233.

19. Seow J, Khan H, Rosa A, Calvaresi V, Graham C, Pickering S, et al. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. Cell Rep. 2022; 40 (8):11276. Epub 2022/08/19. https://doi.org/10.1016/j.celrep.2022.11276 PMID: 35981534; PubMed Central PMCID: PMC9365860.

20. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 183(6):1735. Epub 2020/12/12. https://doi.org/10.1016/j.cell.2020.11.032 PMID: 33306958.

21. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374(6572):abmt0829. Epub 2021/10/15. https://doi.org/10.1126/science.abmt0829 PMID: 34648302; PubMed Central PMCID: PMC8284784.

22. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022; 14(637):eabn8057. Epub 2022/02/16. https://doi.org/10.1126/scitranslmed.aabn8057 PMID: 35166573; PubMed Central PMCID: PMC8939766.

23. Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, et al. Cross-neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020; 53(6):1272–80 e5. Epub 2020/11/27. https://doi.org/10.1016/j.immuni.2020.10.023 PMID: 33242394; PubMed Central PMCID: PMC7687367.

24. Rikhtegan Tehraniz S, Logue J, Newman M, Frieman MB, Harris AD, et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021; 325(14):1467–9. Epub 2021/03/02. https://doi.org/10.1001/jama.2021.3341 PMID: 33646292; PubMed Central PMCID: PMC7922233.

25. Seow J, Khan H, Rosa A, Calvaresi V, Graham C, Pickering S, et al. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. Cell Rep. 2022; 40 (8):11276. Epub 2022/08/19. https://doi.org/10.1016/j.celrep.2022.11276 PMID: 35981534; PubMed Central PMCID: PMC9365860.
Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Munoz Sandoval D, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022; eabq1841. Epub 2022/06/15. https://doi.org/10.1126/science.abq1841 PMID: 35699621.

41. Qu P, Faraone J, Evans JP, Zeng C, Qu P, Faraone J, Zheng YM, Carlin C, et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microbe. 2022. Epub 2022/05/09. https://doi.org/10.1016/j.chom.2022.04.014 PMID: 35526534; PubMed Central PMCID: PMC9101971.

42. Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost. Nature. 2022. Epub 2022/04/22. https://doi.org/10.1038/s41586-022-04778-y PMID: 35441299.

43. Willett BJ, Kurshan A, Thakur N, Newman J, Manali M, Tyson G, et al. Distant antigenic properties of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022. Epub 2022/07/01. https://doi.org/10.1016/j.cell.2022.05.014 PMID: 35526534; PubMed Central PMCID: PMC9035359.

44. Turner JS, O’Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature. 2022. Epub 2022/05/07. https://doi.org/10.1038/s41586-022-04778-y PMID: 35441299; PubMed Central PMCID: PMC9010245.

45. Khan K, Karim F, Cele S, Reedoy K, San JE, Lustig G, et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature. 2022. Epub 2022/05/07. https://doi.org/10.1038/s41586-022-04830-x PMID: 35523247.

46. Kakou CI, Bergeron AJ, Ahlm C, Normark J, Sakharkar M, Forsell MNE, et al. Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection. Sci Immunol. 2022; eabq3511. Epub 2022/05/14. PMID: 35439319; PubMed Central PMCID: PMC9097882.

47. Richardson SJ, Madzorera VS, Spencer H, Mananema NP, van der Mersch MT, Lambson BE, et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022. Epub 2022/04/19. https://doi.org/10.1016/j.chom.2022.03.029 PMID: 35436444; PubMed Central PMCID: PMC9258748.

48. Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell. 2022; 185(9):1572–87 e11. Epub 2022/04/23. https://doi.org/10.1016/j.cell.2022.03.037 PMID: 35426226; PubMed Central PMCID: PMC9258748.

49. Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell. 2022; 185(12):2116–31 e18. Epub 2022/06/07. https://doi.org/10.1016/j.cell.2022.05.014 PMID: 35662412.

50. Tuekprakhon A, Nutalai R, Dijokaita-Guraiuc A, Zhou D, Ginn HM, Selvaraj M, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022. Epub 2022/07/01. https://doi.org/10.1016/j.cell.2022.06.005 PMID: 35752405.

51. Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Munoz Sandoval D, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022; eabq1841. Epub 2022/06/15. https://doi.org/10.1126/science.abq1841 PMID: 35699621.
52. Skowronski DM, Febrani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Clin Infect Dis. 2022. Epub 2022/04/20. https://doi.org/10.1093/cid/ciac290 PMID: 35438175; PubMed Central PMCID: PMC9047203.

53. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1221) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881–91. Epub 2021/02/23. https://doi.org/10.1016/S0140-6736(21)00432-3 PMID: 33617777; PubMed Central PMCID: PMC8078907.

54. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021; 22(6):765–78. Epub 2021/05/01. https://doi.org/10.1016/S1470-2045(21)00213-8 PMID: 33930323; PubMed Central PMCID: PMC8078907.

55. Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021; 11(7):136. Epub 2021/08/01. https://doi.org/10.1038/s41408-021-00528-x PMID: 34330895; PubMed Central PMCID: PMC8232374.

56. Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenele MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021; 27(11):2002–11. Epub 2021/10/02. https://doi.org/10.1038/s41591-021-01542-z PMID: 34594036; PubMed Central PMCID: PMC8004706.

57. McKenzie DR, Munoz-Ruiz M, Monin L, Alaguthurai T, Lechmere T, Abdul-Jawad S, et al. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. Cancer Cell. 2021; 39(11):1445–7. Epub 2021/10/23. https://doi.org/10.1016/j.ccell.2021.10.003 PMID: 34678151; PubMed Central PMCID: PMC8506107.

58. Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2022; 4(1):e42–e52. Epub 2021/11/16. https://doi.org/10.1016/S2665-9913(21)00333-7 PMID: 34778846; PubMed Central PMCID: PMC8577228.

59. Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021; 3(9):e627–e37. Epub 2021/07/15. https://doi.org/10.1016/S2665-9913(21)00212-5 PMID: 34258590; PubMed Central PMCID: PMC8266273 submitted work.

60. Hall VG, Ferreira VH, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K, et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380–5. Epub 2022/02/05. https://doi.org/10.1038/s41590-021-01126-6 PMID: 35115679.

61. Dupont L, Sneli LB, Graham C, Seow J, Merrick B, Lechmere T, et al. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat Microbiol. 2021; 6(11):1433–42. Epub 2021/10/17. https://doi.org/10.1038/s41564-021-00974-0 PMID: 34654917; PubMed Central PMCID: PMC8556155.

62. Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX. 2015; 2:379–84. Epub 2015/11/21. https://doi.org/10.1016/j.jmex.2015.09.003 PMID: 26587388; PubMed Central PMCID: PMC4625112.

63. Thompson CP, Grayson NE, Paton RS, Bolton JS, Lourenco J, Penman BS, et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill. 2020; 25(42). Epub 2020/10/24. https://doi.org/10.2807/1560-7917.ES.2020.25.42.2000685 PMID: 33094713; PubMed Central PMCID: PMC7651873.